Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Lecture: Exploring the androgen signalling pathway in CRPC

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

12 May 2014

Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany;

12 May 2014

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for)

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

12 May 2014

Lecture: Clinical Perspectives: How far are we from personalising treatment for prostate cancer patients?

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

12 May 2014

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against)

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany

12 May 2014

Lecture: Future strategies and targets for prostate cancer

Dr Kurt Miller - Benjamin Franklin Medical Center Berlin, Germany

12 May 2014

Vitamin D as a prevention against breast cancer

Dr Song Yao - Roswell Cancer Center Institute, New York, USA

9 May 2014

Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma

Dr Andrew Davies - Southampton General Hospital, Southampton, UK;

$Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General Hospital, Southampton, UK; )$

9 May 2014

Rituximab versus idelalisib in refractory CLL

Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK

$Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )$

9 May 2014

New agents extend progression-free survival in double refractory myeloma

Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA

$New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA )$

8 May 2014

Aspirin analogues developed for anti-cancer effects on leukaemia

Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK

8 May 2014

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients

Dr Valentin Goede - University of Cologne, Cologne, Germany

8 May 2014

Video

More from ecancer